Financhill
Buy
56

MASI Quote, Financials, Valuation and Earnings

Last price:
$168.16
Seasonality move :
1.61%
Day range:
$165.96 - $171.33
52-week range:
$101.61 - $194.88
Dividend yield:
0%
P/E ratio:
116.80x
P/S ratio:
4.35x
P/B ratio:
8.63x
Volume:
473K
Avg. volume:
571K
1-year change:
27.24%
Market cap:
$9.1B
Revenue:
$2.1B
EPS (TTM):
-$5.70

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MASI
Masimo
$593.3M $1.43 -25.37% 192.38% $193.76
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.26
ARAY
Accuray
$110.4M -$0.04 0.39% -8.33% $6.13
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.33% $115.62
MMSI
Merit Medical Systems
$351.5M $0.83 8.97% 56.02% $118.20
RMD
ResMed
$1.3B $2.31 7.21% 15.65% $269.38
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MASI
Masimo
$168.21 $193.76 $9.1B 116.80x $0.00 0% 4.35x
ABT
Abbott Laboratories
$126.71 $136.26 $219.8B 16.56x $0.59 1.77% 5.28x
ARAY
Accuray
$1.83 $6.13 $188.2M -- $0.00 0% 0.41x
BSX
Boston Scientific
$97.16 $115.62 $143.4B 77.73x $0.00 0% 8.62x
MMSI
Merit Medical Systems
$98.94 $118.20 $5.8B 48.74x $0.00 0% 4.33x
RMD
ResMed
$224.16 $269.38 $32.9B 26.47x $0.53 0.92% 6.71x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MASI
Masimo
42.11% 1.378 8.64% 1.08x
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
ARAY
Accuray
78.56% 2.409 86.22% 0.78x
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
MMSI
Merit Medical Systems
34.59% 1.540 12.84% 2.71x
RMD
ResMed
11.35% 0.169 2% 1.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MASI
Masimo
$244.7M -$54.6M -14.23% -23.05% -58.55% $47.5M
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
ARAY
Accuray
$41.9M $4.7M -2% -9.63% 5.26% $231K
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
MMSI
Merit Medical Systems
$173M $36.7M 5.83% 9.36% 11.58% $64.5M
RMD
ResMed
$751.3M $417.2M 21.74% 25.56% 32.54% $285.2M

Masimo vs. Competitors

  • Which has Higher Returns MASI or ABT?

    Abbott Laboratories has a net margin of -58.2% compared to Masimo's net margin of 84.1%. Masimo's return on equity of -23.05% beat Abbott Laboratories's return on equity of 32.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    MASI
    Masimo
    40.74% -$6.52 $1.8B
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
  • What do Analysts Say About MASI or ABT?

    Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Abbott Laboratories has an analysts' consensus of $136.26 which suggests that it could grow by 7.54%. Given that Masimo has higher upside potential than Abbott Laboratories, analysts believe Masimo is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    MASI
    Masimo
    4 3 0
    ABT
    Abbott Laboratories
    13 6 0
  • Is MASI or ABT More Risky?

    Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.

  • Which is a Better Dividend Stock MASI or ABT?

    Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.77% to investors and pays a quarterly dividend of $0.59 per share. Masimo pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MASI or ABT?

    Masimo quarterly revenues are $600.7M, which are smaller than Abbott Laboratories quarterly revenues of $11B. Masimo's net income of -$349.6M is lower than Abbott Laboratories's net income of $9.2B. Notably, Masimo's price-to-earnings ratio is 116.80x while Abbott Laboratories's PE ratio is 16.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 5.28x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MASI
    Masimo
    4.35x 116.80x $600.7M -$349.6M
    ABT
    Abbott Laboratories
    5.28x 16.56x $11B $9.2B
  • Which has Higher Returns MASI or ARAY?

    Accuray has a net margin of -58.2% compared to Masimo's net margin of 2.18%. Masimo's return on equity of -23.05% beat Accuray's return on equity of -9.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    MASI
    Masimo
    40.74% -$6.52 $1.8B
    ARAY
    Accuray
    36.06% $0.02 $223.4M
  • What do Analysts Say About MASI or ARAY?

    Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Accuray has an analysts' consensus of $6.13 which suggests that it could grow by 234.7%. Given that Accuray has higher upside potential than Masimo, analysts believe Accuray is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    MASI
    Masimo
    4 3 0
    ARAY
    Accuray
    3 0 0
  • Is MASI or ARAY More Risky?

    Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Accuray has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.041%.

  • Which is a Better Dividend Stock MASI or ARAY?

    Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MASI or ARAY?

    Masimo quarterly revenues are $600.7M, which are larger than Accuray quarterly revenues of $116.2M. Masimo's net income of -$349.6M is lower than Accuray's net income of $2.5M. Notably, Masimo's price-to-earnings ratio is 116.80x while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 0.41x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MASI
    Masimo
    4.35x 116.80x $600.7M -$349.6M
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
  • Which has Higher Returns MASI or BSX?

    Boston Scientific has a net margin of -58.2% compared to Masimo's net margin of 12.41%. Masimo's return on equity of -23.05% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    MASI
    Masimo
    40.74% -$6.52 $1.8B
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
  • What do Analysts Say About MASI or BSX?

    Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19%. Given that Boston Scientific has higher upside potential than Masimo, analysts believe Boston Scientific is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    MASI
    Masimo
    4 3 0
    BSX
    Boston Scientific
    23 4 0
  • Is MASI or BSX More Risky?

    Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

  • Which is a Better Dividend Stock MASI or BSX?

    Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MASI or BSX?

    Masimo quarterly revenues are $600.7M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Masimo's net income of -$349.6M is lower than Boston Scientific's net income of $566M. Notably, Masimo's price-to-earnings ratio is 116.80x while Boston Scientific's PE ratio is 77.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 8.62x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MASI
    Masimo
    4.35x 116.80x $600.7M -$349.6M
    BSX
    Boston Scientific
    8.62x 77.73x $4.6B $566M
  • Which has Higher Returns MASI or MMSI?

    Merit Medical Systems has a net margin of -58.2% compared to Masimo's net margin of 7.87%. Masimo's return on equity of -23.05% beat Merit Medical Systems's return on equity of 9.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    MASI
    Masimo
    40.74% -$6.52 $1.8B
    MMSI
    Merit Medical Systems
    48.71% $0.46 $2.1B
  • What do Analysts Say About MASI or MMSI?

    Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 19.47%. Given that Merit Medical Systems has higher upside potential than Masimo, analysts believe Merit Medical Systems is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    MASI
    Masimo
    4 3 0
    MMSI
    Merit Medical Systems
    5 1 0
  • Is MASI or MMSI More Risky?

    Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

  • Which is a Better Dividend Stock MASI or MMSI?

    Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MASI or MMSI?

    Masimo quarterly revenues are $600.7M, which are larger than Merit Medical Systems quarterly revenues of $355.2M. Masimo's net income of -$349.6M is lower than Merit Medical Systems's net income of $27.9M. Notably, Masimo's price-to-earnings ratio is 116.80x while Merit Medical Systems's PE ratio is 48.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 4.33x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MASI
    Masimo
    4.35x 116.80x $600.7M -$349.6M
    MMSI
    Merit Medical Systems
    4.33x 48.74x $355.2M $27.9M
  • Which has Higher Returns MASI or RMD?

    ResMed has a net margin of -58.2% compared to Masimo's net margin of 26.88%. Masimo's return on equity of -23.05% beat ResMed's return on equity of 25.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    MASI
    Masimo
    40.74% -$6.52 $1.8B
    RMD
    ResMed
    58.6% $2.34 $5.9B
  • What do Analysts Say About MASI or RMD?

    Masimo has a consensus price target of $193.76, signalling upside risk potential of 15.19%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 20.17%. Given that ResMed has higher upside potential than Masimo, analysts believe ResMed is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    MASI
    Masimo
    4 3 0
    RMD
    ResMed
    7 7 1
  • Is MASI or RMD More Risky?

    Masimo has a beta of 1.035, which suggesting that the stock is 3.537% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

  • Which is a Better Dividend Stock MASI or RMD?

    Masimo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Masimo pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MASI or RMD?

    Masimo quarterly revenues are $600.7M, which are smaller than ResMed quarterly revenues of $1.3B. Masimo's net income of -$349.6M is lower than ResMed's net income of $344.6M. Notably, Masimo's price-to-earnings ratio is 116.80x while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo is 4.35x versus 6.71x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MASI
    Masimo
    4.35x 116.80x $600.7M -$349.6M
    RMD
    ResMed
    6.71x 26.47x $1.3B $344.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

Sell
50
NUTX alert for Mar 15

Nutex Health [NUTX] is up 14.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock